Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals develops targeted radiotherapies and antibody radiation conjugates designed for patients with hematologic malignancies and solid tumors who have exhausted standard treatment options. The company's clinical-stage pipeline includes Actimab-A for acute myeloid leukemia and myelodysplastic syndromes, Iomab-ACT to condition patients prior to cellular therapies such as CAR-T and gene therapies, and Iomab-B as an induction and conditioning agent for relapsed and refractory acute myeloid leukemia. ATNM-400, a preclinical program utilizing Actinium-225 radioisotope technology, targets prostate cancer indications.

The company collaborates with the National Cancer Institute through a cooperative research and development agreement focused on advancing Actimab-A in acute myeloid leukemia and related myeloid malignancies. Research and development activities also encompass preclinical programs for solid tumor indications beyond the current clinical pipeline.

Actinium Pharmaceuticals operates with approximately 25 full-time employees and maintains headquarters in New York. The company is listed on the NYSE and incorporated in Delaware, with its business model centered on advancing proprietary radiotherapy technologies through clinical development and strategic partnerships with government research institutions.